文献速递前列腺癌

PSMA PET分期盲区:导管内癌在前列腺癌无摄取模式中过表达

The Blind Spot of Prostate-Specific Membrane Antigen Positron Emission Tomography Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.
PubMed 文献 · J Urol · 2025-09-05

本研究为双中心回顾性队列,纳入178例根治性前列腺切除术前接受前列腺内PSMA PET的患者,评估PRIMARY评分1(无摄取模式)者的组织病理学及导管内癌(IDC-P)患病率。

要点

  • PRIMARY评分1(无摄取)患者中IDC-P发生率显著高于有摄取者(40% vs 21%)。
  • PRIMARY评分1且伴IDC-P者病理分级组≥3比例达100%,高于不伴IDC-P者的33%。
  • 因不良临床、PI-RADS或活检特征拟行根治术者,PSMA PET无摄取不应视为小体积或低级别疾病的标志。

核心结论

  • 在拟行根治性前列腺切除术的患者中,PSMA PET显示前列腺内无摄取模式不应被视为小体积或低级别疾病的固有标志。
  • 部分高级别前列腺癌,尤其伴IDC-P者,可能在PSMA PET上显示不佳。

研究设计与样本

  • 双中心回顾性队列研究,纳入178例根治性前列腺切除术前接受前列腺内[68Ga]Ga-PSMA-11或[18F]DCFPyL PSMA PET的连续患者。
  • PSMA PET均由核医学医师集中审阅,记录PRIMARY评分及定量影像参数,并收集围手术期特征、PI-RADS及组织病理学。

主要发现

  • PRIMARY评分1(无摄取模式)见于30例(17%)患者。
  • PRIMARY评分1亚组中,伴IDC-P者病理分级组≥3疾病比例高于不伴IDC-P者(100% vs 33%)。

关键数值与推荐

  • PRIMARY评分1定义为前列腺内PSMA PET无摄取模式,PRIMARY评分≥2定义为有摄取模式。

临床怎么用

  • 对于因不良临床、PI-RADS或活检特征拟行根治性前列腺切除术的患者,PSMA PET无前列腺内摄取模式不应被解释为小体积或低级别疾病。
  • 需警惕部分高级别前列腺癌(尤其伴IDC-P者)在PSMA PET上可能显示不佳,应结合临床、MRI及活检病理综合评估。

局限性

  • 研究选择的是PRIMARY评分1且后续接受手术的患者,限制了结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is increasingly used to diagnose and stage prostate cancer. A PRIMARY score uses anatomical localization and uptake patterns to improve diagnostic accuracy. We evaluated the histopathology of patients with no uptake pattern (PRIMARY score 1) and the prevalence of intraductal carcinoma of the prostate (IDC-P) in this subset compared with those with an uptake pattern (PRIMARY score ≥2). MATERIALS AND METHODS: A 2-center, retrospective cohort study was conducted including consecutive patients imaged with intraprostatic [68Ga]Ga-PSMA-11 or [18F]DCFPyL PSMA PET before radical prostatectomy. All PSMA PET scans were centrally reviewed by nuclear medicine physicians, with PRIMARY scores and quantitative imaging parameters recorded. Perioperative characteristics, Prostate Imaging Reporting and Data System (PI-RADS), and histopathology were collected. The distribution of grade group and other histopathological findings, including IDC-P, were examined according to PSMA uptake patterns. RESULTS: A total of 178 patients were analyzed. A PRIMARY score 1 finding on intraprostatic PSMA PET was seen in 30 (17%) patients. IDC-P in prostatectomy specimens was more frequent in these patients compared with PRIMARY score ≥ 2 patients (12/30, 40% vs 31/148, 21%; P = .026). In the PRIMARY score 1 subset, patients with IDC-P had considerably more pathological grade group ≥ 3 disease than those without IDC-P (100% vs 33%). Eighty-one percent of all patients had PI-RADS scores 4 or 5 on prebiopsy MRI. The study's generalizability is limited by the selection of patients with PRIMARY score 1 disease who subsequently proceeded to surgery. CONCLUSIONS: In patients who are being considered for radical prostatectomy due to adverse clinical, PI-RADS, or biopsy features, a PSMA PET demonstrating no intraprostatic uptake pattern should not be considered inherently a marker for small-volume or lesser-grade disease. Some high-grade cancers, particularly those associated with IDC-P, may not be well visualized on PSMA PET.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chen DC, Alhamdani Z, Papa N, et al. The Blind Spot of Prostate-Specific Membrane Antigen Positron Emission Tomography Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer. J Urol. 2025. PMID: 40910488. doi:10.1097/JU.0000000000004734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。